Bank of America Boosts Danaher (NYSE:DHR) Price Target to $270.00

Danaher (NYSE:DHR) had its price target lifted by stock analysts at Bank of America from $258.00 to $270.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the conglomerate’s stock. Bank of America‘s price objective would suggest a potential upside of 7.83% from the company’s previous close.

DHR has been the subject of several other reports. Royal Bank of Canada upped their target price on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Raymond James upped their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. KeyCorp boosted their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. TD Cowen raised their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Barclays upped their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $269.38.

Danaher Stock Performance

Shares of DHR stock traded down $2.72 during trading on Wednesday, reaching $250.39. The company had a trading volume of 1,285,176 shares, compared to its average volume of 2,757,865. Danaher has a one year low of $182.09 and a one year high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The firm’s 50 day simple moving average is $248.95 and its two-hundred day simple moving average is $230.64. The company has a market capitalization of $185.42 billion, a PE ratio of 39.15, a PEG ratio of 3.96 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the company earned $2.36 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. Sell-side analysts forecast that Danaher will post 7.62 earnings per share for the current year.

Insider Activity at Danaher

In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,957 shares of company stock worth $8,265,802. 10.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Banco Santander S.A. acquired a new stake in shares of Danaher in the third quarter valued at about $683,000. First Citizens Bank & Trust Co. raised its stake in shares of Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after buying an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Danaher by 4.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after buying an additional 142 shares in the last quarter. Finally, Keybank National Association OH raised its position in Danaher by 0.5% during the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after acquiring an additional 2,567 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.